Triple Agonists (GLP-1/GIP/Glucagon) Adverse-Event Management Protocols

Is any triple agonist approved?

No FDA-approved retatrutide product was found. Retatrutide and cagrilintide cannot be used in compounding under federal law, and FDA says neither has been found safe and effective for any condition [3]. The approved product that activates both GIP and GLP-1 receptors is tirzepatide (Mounjaro, Zepbound), which its label calls a GIP and GLP-1 receptor agonist: a dual agonist, not a triple one [4].

What the labels do about stomach side effects

Stomach reactions top the adverse-reaction tables. In Wegovy weight trials at 2.4 mg, nausea occurred in 44% vs 16% on placebo, diarrhea in 30% vs 16%, vomiting in 24% vs 6% and constipation in 24% vs 11% [1]. With orforglipron 17.2 mg, nausea was 35% vs 10%, diarrhea 25% vs 11% and vomiting 24% vs 4% [2].

Both labels use slow escalation as the main defense. The Wegovy label steps up the dose in 4-week stages and says to consider delaying escalation for 4 weeks if a dose is not tolerated [1]. The Foundayo label keeps each dose for at least 30 days and says to reinitiate escalation at a lower dosage if 7 or more consecutive doses are missed [2]. The Foundayo label reports severe GI reactions in about 3% of treated patients vs 1% on placebo, and both labels say the drugs are not recommended in severe gastroparesis [2][1]. In the weight trials, 6.8% on Wegovy 2.4 mg vs 3.2% on placebo stopped for adverse reactions [1], and 8% vs 3% stopped orforglipron, most of them for GI reasons [2].

Which side effects the labels treat as serious

• Pancreatitis: both labels say to discontinue if pancreatitis is suspected and describe symptoms as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1][2].
• Kidney injury from dehydration: the labels describe acute kidney injury, mostly after GI reactions causing volume loss, and say to monitor renal function in patients reporting reactions that could lead to volume depletion; the Foundayo label adds especially during dosage initiation and escalation [1][2].
• Gallbladder disease: in Wegovy adult weight-reduction trials, cholelithiasis was reported by 1.6% of injection patients vs 0.7% on placebo, and cholecystitis by 0.6% vs 0.2% [1].
• Low glucose with insulin or a sulfonylurea: the labels advise considering a lower dose of the insulin or secretagogue when starting [1][2]; in the orforglipron type 2 diabetes trial, glucose below 54 mg/dL occurred in 7% of patients on a sulfonylurea vs 0.5% of those not on one [2].
• Heart rate: the Wegovy label says to monitor heart rate at regular intervals; mean resting heart rate rose 1 to 4 bpm with Wegovy, 4 to 5 bpm with orforglipron vs 0.5 bpm on placebo, and 1 to 3 bpm with tirzepatide [1][2][4].

Does the glucagon component add its own side effects?

A rodent study reported a single peptide that activates GLP-1, GIP and glucagon receptors and reduced body weight and reversed hepatic steatosis in obese rodent models [5]. In 13 human volunteers given 120-minute infusions of GLP-1 plus glucagon at individually subanorectic doses, food intake fell 13%, GLP-1 protected against glucagon-induced hyperglycemia, and energy expenditure rose 53 kcal/day [6]. The study reports intake, glucose and energy expenditure, not side-effect rates, so it does not show whether glucagon adds heart-rate, blood-pressure or liver effects.

Oral medicines and birth control

GLP-1 labels state that these drugs delay gastric emptying and may change absorption of oral medicines, and advise closer monitoring for drugs with a narrow therapeutic index [1][2]. The Zepbound (tirzepatide) label advises a non-oral or added barrier contraceptive method for 4 weeks after starting and after each dose increase; Foundayo says the same for 30 days [4][2]. Semaglutide labels carry no such advice [1].